Results obtained in a phase I clinical study of the new drug were presented in Berlin, on November 19th, at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. ACE-041 aims at the receptor known as ALK-1 (activin receptor-like kinase-1), which is responsible for regulating the formation of new networks containing blood vessels that are needed for the growth of tumours. This process is known as angiogenesis. Existing anti-angiogenic drugs, including sunitinib, bevacizumab and sorafenib are targeting other angiogenesis receptors like VEGF, while ACE-041 is among the first drugs to target the ALK-1.

Professor Sunil Sharma, who is the Jon and Karen Huntsman Presidential Professor of Cancer Research at the Huntsman Cancer Institute of the Utah University in Salt Lake City, USA, said that the connection between angiogenesis and ALK-1 was made by discovering that mutations in the ALK-1 gene had caused a condition named HHT2 (hereditary haemorrhagic telangiectasia 2, characterised by diminished formation of capillary beds, which causes red markings at the level of the skin.

A technology company in Cambridge, Massachusetts, USA, Acceleron Pharma, has designed ACE-041 aiming to inhibit ALK-1 signalling and has asked Professor Sharma to be one of the investigators who would conduct the first-in-man phase I clinical test of the drug in order to see if it really would halt tumour angiogenesis.

Professor Sharma said that since ALK-1 was transiently expressed on proliferating cells lining the inner surface of the blood vessels (endothelial cells), while VEGF receptors were constitutively expressed on endothelial cells and other types too, it would be a more selective target when trying to inhibit angiogenesis. ALK-1 expression on the vasculature of the tumour has been noticed on biopsy samples of a wide range of tumours.

The phase I of the study comprised patients with a diversified range of advanced solid tumours that already spread to other parts of the body or simply were inoperable like multiple myeloma, neck and head cancers, NSCLC (non-small cell lung cancer) and carcinoid tumours (carcinoma type neuroendocrine tumours usually originating in the appendix or small intestine). Many of the patients had been unsuccessfully treated with a series of other treatments, which included anti-VEGF drugs, before this trial. ACE-041 has been administrated via subcutaneous injections.

Professor Sharma said that, early in September, 25 patients have been included in the study and ACE-041 dose level has been escalated from 0.1 mg/kg to 4.8 mg/kg. In the case of a patient with neck and head cancer, the response was partial, while three patients have shown positive responses as determined by FDG-PET scans. ACE-041 has been well tolerated by the patients, with some adverse events like peripheral oedema, anaemia, headache, nausea and fatigue.

Seeing many signs of efficacy during the trial has been quite encouraging for the medical team, particularly because of the structure of the study population. They were patients with end-stage cancer, already treated with and refractory to multiple standard therapies. It has equally been encouraging to note signals of activity of ACE-041 in a wide series of tumour types, thus confirming the hypothesis that ACE-041 may really act against tumours with agiogenic activity, no matter what histology they had. Another important aspect to be noted was the demonstration of the significant activity with ACE-041 monotherapy during the study, which leads to expectations of more efficacy in future studies including ACE-041 combined with other therapies.

Professor Sharma and his team planned further investigations related to the safety and tolerability of ACE-041 in an additional group of cancer patients and look forward to start a phase II study in 2011.

According to Professor Sharma, the anti-VEGF angiogene inhibitors, which include sunitinib, bevacizumab and sorafenib, have represented an important contribution to the armamentarium of therapies against cancer. However, the efficacy is in a way limited because tumours could eventually develop an ability to simulate angiogenesis using non-VEGF angiogenic factors. Serious side-effects appear from effects on blood vessels found in normal tissues. ACE-041 inhibits angiogenesis in a totally different way and therefore it might have synergistic efficacy with VEGF-based inhibitors. It may be effective for patients who have manifested resistance to VEGF inhibitors.

In the United States, lung cancer is the second most found type of cancer. It accounts for more dead people than prostate, breast and colon cancer together, as data from the Centers for Disease Control and Prevention show. Many patients follow more than a single type of treatment for lung cancer, which can last for some weeks to months.

Raimar Löbenberg, lead researcher, and his team mates Wilson Roa and Warren Finlay from the University of Alberta, using a usual chemotherapy drug which was encapsulated into nanoparticles, developed a dry powder to be inhaled.
A number of mice were treated with this powder and others received the same drug through two distinct delivery methods, consisting of a solution and intravenous injection of drug bound nanoparticles.

Results have shown the inhalable dry powder as being more effective than the solution or the intravenous injection. According to the study, more than eighty percent of the mice lived more than ninety days. More than seventy percent of the mice lived for 140 days. At the same time, none of the animals treated with the solution or the intravenous injection survived more than fifty days.

Löbenberg said that current treatments for lung cancer could cost the patient a lot. The research showed that the new treatment method might increase the survival rate and at the same time could be less toxic for the patients’ bodies.

The new inhalable dry powder also proved its efficiency versus the intravenous injection in reducing both the amount and the size of tumors. The animals not treated or treated with the solution or intravenous injection presented large tumor masses, while mice treated with the inhalable dry powder showed significantly fewer and also smaller tumors.

The investigation was released in the Cancer Research journal in its October edition. The investigators from the University of Texas Southwestern Medical Center discovered that if they gave the mice the BEZ235 medication prior to undergoing harmless radiation in order to counteract the cancerous cell development of DNA, the BEZ235 would counteract the activity of the PI3K protein which typically acts as a guardian of the tumor cells. This protein maintains the cancerous cells in life in the moment they are attacked and try to heal their broken DNA.

Besides the leading author, the team of investigators from the University of Texas comprised: doctor Erik Bey from the Harold C. Simmons Comprehensive Cancer Center, doctor Andrea Rabellino, doctor Katja Schuster, doctor Adi Gazdar, professor within the University of Texas Southwestern, Jake Hamon from the Center for Therapeutic Oncology Research, doctor David Boothman from the Simmons Comprehensive Cancer, researchers coming from the University of Camerino in Italy and Novartis Pharma in Switzerland. Their investigation was financed by funds coming from National Institutes of Health, American Cancer Society, Concern Foundation, Gibson Foundation, Leukemia of Texas, United States Department of Energy and the American Italian Cancer Foundation.

The scientists observed this treatment opportunity in mice that underwent a transplant process with non-small cell lung cancer tumors from human beings.

During their observation process, the researchers discovered that the malignant tumors developing in the mice which were treated with just the BEZ235 has a decrease in size compared to those affecting mice which were not undergoing any type of treatments. Even though the malignant tumors did not grow in size, their life was not ended by administering the specific medication.

On the other hand, mice undergoing the BEZ235 treatment combined with low-dose radiation recorded many cases of total elimination of the malignant tumors.

The leading investigator was doctor Pier Paolo Scaglioni who is assistant professor of the internal medicine department within the University of Texas Southwestern. He stated that the findings of his research team regarding the combination of medication and low-dose radiation may prove to become an efficient treatment for counteracting non-small cell lung cancer in human beings.

The non-small cell lung cancer represents one of the main causes of cancer connected mortality on the whole Globe. The malignant cells usually favor transformations in the K-RAS which is a gene. People suffering from mutations of the K-RAS usually present an increased resistance to therapies comprising irradiation. This is the cause for which their life perspectives are unfavorable.

The K-RAS transformations trigger the networks or different pathways of various proteins that act as signals to activate. This signaling represents a key element in the development and growth of a malignant tumor. The PI3K represents just one of these proteins. At the moment of activation, it acts as a guardian which aids the cells in maintaining living functions even after their DNA was damaged and they try to heal it.

Some of the elements forming the signal networks comprising also the PI3K protein have been explored as various medication targets for counteracting malignant tumors. The clinical tested medication BEZ235 has been recently in experiments comprising clinical tests for counteracting the activity of the PI3K and the mTOR which represents a signaling protein, also.

As the leading investigator states there is no efficient treatment counteracting the non-small cell lung cancer which hosts transformations of the K-RAS.

Medical doctor Pier Paolo Scaglioni conducted the first tests in order to identify the efficacy of the BEZ235 drug and thus, they tested it alone. The team of investigators discovered that the BEZ235 stops the evolution and growth of the lung cancer malignant cells that were developed in the laboratory and the malignant lung cells that affect the mice.

As the leading author of this first research, doctor Georgia Konstantinidou states the findings of the investigators were shocking. However, they strived to discover a way for a faster malignant cell deterioration. They found put that by combining the tested medication with low-dose radiation, the success of their mission was assured. Doctor Georgia Konstantinidou is a post-doctoral scientist within the University of Texas Southwestern.

Doctor Pier Paolo Scaglioni`s research group observed that the malignant cells which were treated with the BEZ235 medication and low-dosed irradiation. The latter triggered slight breaks in the cellular genetic material but did not managed to affect them in a more effective way in order to destroy them. At the moment the DNA of the cell is broken, the malignant cells are aided by the PI3K signaling network in order to assure the cancer cell`s survival while it is healing its genetic material.

The team of investigators explained that the malignant cells needed the PI3K signaling pathway to assure they remain alive and without the protein`s response they were prone to die. This is why in the moment the scientists administered the BEZ235 medication it stopped the action of the PI3K protein and this means that the non-small cell lung cancer cells were starting to die.

As the leading author of the research explains the future stage of the study is that of administering the BEZ235 medication or similar drugs in clinical tests against the non-small cell lung suffering human beings. This could also be applied in clinical trials comprising people suffering from other types of malignant cells such as pancreatic, colon and thyroid cancers. There are the same with the non-small cell lung due to the fact that the PI3K signaling network also acts as an important agent in the malignant cells` evolution.

This environmental report is just a part of the process of taking care of the continuous and newly discovered problems regarding the pollutant agents of the environment and cancer. Moreover, the scope of the report is to shed more light on the principles, mission, values, objectives and various roles of the American Cancer Society on issues such as those mentioned before: pollution and malignant tumors prevention.

As the co-chair of the subcommittee and chairman of the Department of Preventive Medicine within the Keck School of Medicine of University of Southern California, medical doctor Jonathan Samet explains the problems regarding the environmental pollution agents affecting the air, water, food and thus, customer products represent issues on general public care and high unknowns. He also adds that their report aims to put the pollution agents of the environment in a greater relationship with preventing malignant tumors. The relationship focuses on reducing the smoking habit of the population, improving nutritional behavior, increasing the physical activities, maintaining a proper body weight and come up with vaccines that counteract the infections which may cause cancers.

The other co-chair of the subcommittee is also volunteer president of the American Cancer Society. Her name is Elizabeth “Terry” T.H. Fontham and she stated that the exposure levels of the population to chemical and pollution agents affecting the environment are much lower than the levels linked to the showed predisposition to developing malignant tumors in the jobs people have and other daily settings. However, the concern raised by the low exposure levels has to do with the fact that the number and types of pollution substances are increasing and may prove in the future to get out of the population`s control. In addition, the problems related to the fact that even low exposure levels bring some contribution to the cancer developing cases cause more reasons for distress considering the high number of persons who are daily exposed to the environmental pollutants.

The subcommittee`s report states that the scientific problems related to the exposure of people to the environmental pollutants represent complex issues just like increase in the number of landscape technologies which are utilized to analyze the chemical carcinogenicity. In spite of the capability of the nowadays tools used to identify and categorize proves for carcinogenicity, the subcommittee`s article states that there exist three main problems which constrain them from using them because there is a limited quantity of resources which are allotted to function those specific systems and from a scientific point of view, the environmental problems are complex and uncertain.

The report`s concerns about cancer vary and are related to malignant tumors prevention. There is a high need for new stratagems related to the tests done to evaluate the environment`s toxicity, comprising also the evaluation of carcinogenicity. These new strategies could be incorporated in such a manner as to assure a more efficient and effective screening process of a higher number of chemical agents which affect people daily. In addition, exposure to occupational and community settings should be regulated by some standards. The subcommittee draws attention on the need to support investigations aimed at identifying and decreasing the number of hazards provoked by carcinogens. Furthermore, the institutions that determine and implement standards for the environment must meet proper financing and appropriate technology in order to be near the scientific evolution and upgrade their set standards according to the new available data.

Even though some exposure cannot be avoided, this type of exposure must be somehow diminished and even stopped in the cases where it is possible to do so. In addition, the population must receive information about these matters in order to know their health status and risk of cancer or other diseases. Last, but not least, the media communication must make people aware of the situation of the exposure in an accurate manner and not to exaggerate or diminish the importance and level of environmental pollution factors.

The subcommittee’s report states that in order to create and implement this new initiative in order to assure the acquiring of more knowledge regarding the association between the levels of exposure to environmental pollution agents and the predisposition to various types of cancers, the American Cancer Society is going to further develop its long-run commitment to preventing malignant tumors. In addition, the American Cancer Society is also keen on studying these problems more thorough in order to discover new ways in which the initiative could bring more benefits in an effective and efficient manner.

The investigation of the Swedish researchers is released in the Arthritis & Rheumatism in the November edition which is a journal of the American College of Rheumatology by Wiley-Blackwell.

The tumor necrosis factor is a solution produced by the body`s immune system cells entitled cytokine. This substance has the role of regulator of the immune system and plays a great part in the inflammation process. Tumor necrosis factor inhibitors also known as blockers of the tumor necrosis factor represent a group of treatments that is utilized in counteracting swellings in chronic swellings such as the rheumatoid arthritis. The standard immunosuppressant medications and those comprised in the investigation are Enbrel®, Remicade® and HumiraTM. Due to the fact that these treatments are utilized in order to counteract the chronic swelling diseases, the long-run inhibition of the tumor necrosis factor determines debates on the enhanced predisposition to cancer or various infections.

The Swedish investigation represents one of the biggest and long lasting evaluations of the population in verifying the predisposition of developing malignant tumors linked to treatments that comprise immunosuppressive medications. The research incorporated information coming from various Swedish databases such as the Cancer Register, the Biologics Register and the Early RA Register.

The group of scientists observed and evaluated the data coming from 6,366 people who began anti- tumor necrosis factor treatment on a period ranging between January 1999 and July 2006. The information coming from patients who underwent tumor necrosis factor inhibiting therapies was later compared with some other groups of people who suffered from rheumatoid arthritis. These groups comprised 61,160 people who did not take any kind of drugs, 4,015 patients using the gold standard rheumatoid arthritis therapy entitled methotrexate and 4,015 individuals who took combinations of anti- rheumatoid arthritis medications that were known to modify the illness but different from the drugs inhibiting the tumor necrosis factor.

The outcome of the large investigation was that 240 first main cancers were diagnosed during the 25,693 human-being years of tracking in the people who underwent anti- tumor necrosis factor treatments who did not present any history of malignant tumors at the outbreak of the immunosuppressant drug therapy. In comparison with the bigger national rheumatoid arthritis group who did not get tumor necrosis factor inhibitor medications or who had developed malignant tumors in the past, the relative predisposition to develop cancer for patients who underwent anti- tumor necrosis factor treatments was 1.00 and did not change for the persons who took immunosuppressant medications for even six years.

As the leading investigator states their research pointed out the overall predisposition to cancer was the same for people who developed rheumatoid arthritis and were currently undergoing immunosuppressant treatments and those patients who did not take that type of medication in counteracting their illness. In addition, doctor Askling states that there are some uncertainties that remain under the sing of the doubt and recommends vigilance in these treatments in order to assure that nothing goes wrong.

The rheumatoid arthritis represents an autoimmune illness that has as symptoms chronic swelling of the joint, joint tissues and other organs. The RA is one of the most widely spread variant of swelling arthritis. Statistics released in 2004 by WHO (World Health Organization) stated that approximately 23.7 million individuals all over the Globe, from which 1.3 adults from the United States, suffered from rheumatoid arthritis. 75 percent of the 23.7 million cases represented the female gender.

An investigation set up on the “Asian paradox” was released in the World Journal of Gastroenterology in this year`s October edition. The investigation was led by medical doctor Murdani Abdullah who activates in the Division of Gastroenterology, Department of Internal Medicine within the University of Indonesia. The research started from an earlier concept developed by P. Correa. This is concerned with the fact that there are some changes in the mucosa triggered in a cascade manner which are triggered either by acute or chronic gastritis and develop into gastric malignant tumors.

The variations in the way Helicobacter pylori affects the gastric tract and produces gastritis might provide the explanations of the variety of gastric malignant tumors incidence between Japan and Indonesia, for example. Earlier research never took a closer eye at these transformations of the gastric mucosa which later developed into gastric cancer.

The recent investigation strives to observe the changes that occur in the gastric mucosa at the time when it is infected with Helicobacter pylori and develops gastric malignant tumors. The transformations of the gastric mucosa were observed in two Asian countries that present the “Asian paradox”: Japan and Indonesia.

Starting with the year 1998, 42 sick people from the Yamanashi Medical University Hospital located in Koufu and 125 patients from the Metropolitan Medical Centre Hospital located in Jakarta were enrolled for the period of one year (the duration of the research). Out of this investigation, it has been discovered that there is a complex variation in the activity and degree of the transformations that occurred in the gastric mucosa among the Japanese and Indonesia patients who underwent the study and tested positive for Helicobacter pylori. These discoveries may mean that the Indonesian and the Japanese population affected by the Helicobacter pylori infection present different responses to the infections.

The scientists who underwent this investigation think that agents that appear and affect people`s way of living and their genetic history are essential elements that trigger the “Asian paradox”. However, further researches need to be done in order to gather more information and knowledge about this matter and thus, to better understand the variations in patients suffering from infections with the Helicobacter pylori.

The COX-2 (Cyclooxgenase-2) represents an enzyme which synthesizes prostaglandin. An evolved expression of Cyclooxgenase-2 is found in a great variety of malignant tumors affecting human beings which also comprise the gastric cancer. Experiments done on animals revealed that a long-term treatment with medication that inhibits the gastric carcinogenesis related to Cyclooxgenase-2. However, using such inhibiting drugs on humans is still not done due to the fact that the medication can trigger harmful and even fatal cardiovascular side-effects. This is why it is of great importance to discover the best and harmless therapy comprising Cyclooxgenase-2 inhibiting medications that also inhibit the Helicobacter pylori linked to gastric carcinogenesis.

A recent study regarding this matter was released in the World Journal of Gastroenterology in the October edition. Professor Wu coming from the Department of Gastroenterology within the Kaohsiung Medical University Hospital was the leader of the investigation. He utilized the Mongolian gerbil model in order to observe the best point of Cyclooxgenase-2 inhibiting medication for inhibiting gastric carcinogenesis produced by Helicobacter pylori. This new research also takes a closer look at the chemotherapy use for preventing this condition and also at the adverse effects the Cyclooxgenase-2 inhibiting medication may produce to the human body.

Earlier investigations utilized chemotherapies on a long-run basis for preventing the gastric carcinogenesis. Nonetheless, the Cyclooxgenase-2 inhibiting drugs did not come in placebo format and affected the patients. This group of medications must not be utilized on a long-run basis in the chemoprevention of the gastric malignant tumors.

As the investigation pointed, Celecoxib is a drug which might trigger anti-oncogenic effects. It can also inhibit the angiogenesis and the spreading of malignant tumors in the whole body. Moreover, this medication proved to be efficient in obtaining these effects either if it was used on a short- or a long- term basis. Celecoxib acted as a guardian who connotes an early oncogenic stage and not an inflammatory one. In addition, the utilization on short-term of Celecoxib proved to bring harmless inflammations and also stopped the spreading of gastric malignant cells in the organism.

If we were to listen to what the investigation has to say, the short- and long-term use of Celecoxib for counteracting Helicobacter pylori` infection pathway in a medical case is the best thing to do. This finding has been never present in earlier researches. Thus, the new discovery is essential in diminishing the adverse effects produced by Cyclooxgenase-2 inhibiting drugs.

The team of investigators state that Cyclooxgenase-2 inhibiting medication might be utilized as a chemoprevention treatment for patients that are 40 years or older. This approach may prove to play an essential part in the life of patients who suffer from extended metaplastic gastritis with an enhanced predisposition of developing gastric malignant tumors. Moreover, the therapy is essential also for people who suffer from refractory Helicobacter pylori infections with an increased predisposition for gastric malignant tumors.

As a gastroenterological specialist stated the research outcome provides new insights into a customized treatment against gastric malignant tumors starting with the prevention phase and also it may bring advantages for medical therapy in the near future.
.

Earlier research which observed people that were not Jewish took a closer look at the association between the cancer occurrence rates and the psychological and physical stress which ranged from famine to mental ones. However, these past investigations did not managed to reach a conclusive outcome.

Lital Keinan-Boker who is a medical doctor in the School of Public Health, Faculty of Welfare and Health Sciences within the University of Haifa located in Israel, led a team of investigators in a research regarding the above mentioned association. The group of scientists observed a sample of approximately 300,000 Jews coming from Israel. A particularity of these Jews was the fact that they were born in Europe, but later, before and during the World War II they moved in Israel. One of the groups was exposed to the Holocaust, whereas the other one was not. The group which experienced the Holocaust was determined as such by taking into consideration their immigration to Israel dates, due to the fact that specific information about the exposure to the massacre experience was not available.

The thought exposure to the Holocaust was linked with an enhanced predisposition to cancer as a whole considered for all the born groups and both for males and females, in comparison with the cohort which was not exposed to this massacre. The most important links between cancer and Holocaust exposure were comprised by two types of malignant tumors: breast and colorectal. For example, the exposure at an earlier age appeared to be specifically linked to the enhanced predisposition to develop any particular case of cancer.

As the investigators of the research state that their findings come as direct shock information for all the Jewish people who survived the Second World War and as a consequence they are very important for the physicians of these patients all over the world and especially Israel due to the high immigration rates. The team of researchers sees its discoveries as a warranty for all the investigations that would arise on this subject in the future. They expect to see research done on case-control studies which would generate answers and more information and also state that their study presents past and actual agents of risk that may bias the study when utilizing individual information to investigate this matter.

A complementing editorial to this study is written by Stephen Hursting from the Department of Nutritional Sciences at the University of Texas and Michele Forman from the Department of Epidemiology, University of Texas, also activating in MD Anderson Cancer Center located in Houston. The two compare the outcomes of the above mentioned study and other researches from the past which presented the association between the reduction of eaten calories and the predisposition to cancer. Hursting and Forman state that the information acquired from the newer investigation comes as a supplement for the existing published data regarding the effects of a harmful reduction of daily and necessary calories that one eats and the cruel physical and psychological stress this practice is prone to produce in human beings.

As the editorialists explain, by putting alongside information coming from investigations done on animals and human beings it seems that even though by reducing the daily intake of calories may reduce also the risk of developing malignant tumors, these rather beneficial effects against cancer are diminished and even destroyed by the exposure to a very demanding and stressful experience. Furthermore, the two state that by studying the group of Jewish persons who were exposed to the cruel experience of the Holocaust during the first years of their life, a great deal of knowledge can be acquired about stress effects at a younger age, adaptation ability and predisposition to cancer after years passed from a very stressful experience.

The investigation was released in the Alcoholism: Clinical and Experimental Research edition. The study comprises the researchers` findings regarding how alcohol triggers the epithelial-to-mesenchymal transition. During this transition, the mild cancerous cells transform in aggressive one and start invading the whole body in a process entitled metastasis.

As assistant professor Christopher Forsyth from the medicine and biochemistry division within the Rush University Medical Center explains the information provided by the team of investigators led by him is the first of its kind. This is due to the fact that their data presents the pathway in which alcohol stimulates specific triggers within a cell which are implicated in the metamorphosis into an aggressive form of the cells.

The notion of epithelial-to-mesenchymal transition is a highly researched matter nowadays due to the fact that it represents one of the processes involved in the mechanism of cancer spreading in the whole organism. An amalgam of laboratory investigations and clinical trials shows that this epithelial-to-mesenchymal transition is a prime factor in triggering the aggressiveness of the cancerous cells.

Professor Christopher Forsyth stated that the malign cells acquire a dangerous characteristic in the moment when they start spreading in the whole body. The operations can resection a malign tumor, but the aggressive cells have the ability to spread out in the whole human organism and conquer it. If medical doctors could stop this process, they would be able to limit the spreading of the malignant tumors.

The team of investigators put alcohol in cellular lines coming from colon and breast cancers and observed them in order to find the biochemical distinct signs of the epithelial-to-mesenchymal transition also including the presence of both Snail which is a transcription agent and the receptor concerned with the growth agent of the epidermis. The Snail represents the epithelial-to-mesenchymal transition`s control factor. On experiments undergone on mice, it was observed that if there is an over-expression of this factor, multi tumors are prone to develop. The second agent, the epidermal growth one is just like a drug for the cancer cells, they require large quantities of it.

The testing undergone in laboratories proves that alcohol triggered both factors and also other biochemicals agents related to the epithelial-to-mesenchymal transition. The trials also proved that the cells which were put in alcohol lost their strong links to adjacent cells, a characteristic which resembles the metastasizing process of the malign tumors.

Furthermore, professor Christopher Forsyth`s team of researchers discovered that the similar group of biomarkers was triggered in healthy intestinal cells which were put in alcohol. In addition to the aggressive metamorphosis alcohol triggers in cancer cells, this finding could mean that alcohol may also trigger the development of cancer.

The results of the research are based on a case-control investigation of people from New Hampshire. The outcomes and discoveries of the investigation were released in the British Journal of Cancer`s September edition. The leading author of the investigation is Karl Dietrich who is a student within Dartmouth Medical School. Accompanying him are professors: Alan Schned, John Heaney and Margaret Karagas who is also a professor in the Dartmouth Medical School in the family and community medicine department.

The research investigates the utilization of glucocorticoids on a long-term basis. The studied sample comprised 786 people suffering from bladder-cancer and 1,083 people who represented the control group. The amalgam of cytotoxic and glucocorticoids medications is recommended and prescribed by physicians in immunosuppressive treatments in order to aid ill people who underwent organ transplants to counteract the body`s rejection of the foreign organ. In addition, the glucocorticoids are also prescribed to people who suffer from asthma, rheumatoid arthritis and various other diseases.

Earlier investigations, some of which included Margaret Karagas as fellow researcher, reported links between these types of medication treatments and an increased predisposition to lymphoma and skin cancers.

As the new investigation presents the predisposition of developing bladder malignant tumors associated with the above mentioned therapies may be an indicator for the need of taking a closer look at patients who constantly take glucocorticoids as part of their treatments.